Osiris Phleum pratense

Drug Profile

Osiris Phleum pratense

Latest Information Update: 10 Jun 2015

Price : $50

At a glance

  • Originator ALK-Abello
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Seasonal allergic rhinitis

Most Recent Events

  • 29 Feb 2012 ALK-Abelló completes a phase II trial in Seasonal allergic rhinitis in Poland (NCT01425788)
  • 10 Feb 2012 ALK-Abello completes enrolment in its phase II trial for Seasonal allergic rhinitis in Poland (NCT01425788)
  • 29 Aug 2011 Phase-II clinical trials in Seasonal allergic rhinitis in Poland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top